Key pointsInfiltration of immunosuppressive innate immune cells such as TAMs and MDSCs in CCA is associated with poor patient outcomes.T cell-infiltrated or immune 'hot' CCAs have increased CD8+ T cell infiltration with enhanced interferon γ and granzyme B activity, increased expression of immune checkpoint molecules such as PD-1 and its ligand PD-L1, and enhanced responsiveness to ICB.Non-T cell-infiltrated or immune 'cold' CCAs are devoid of CD8+ T cells and have a preponderance of immunosuppressive cells such as TAMs, MDSCs, and tolerogenic DCs.Conventional chemotherapy has limited efficacy in metastatic cholangiocarcinoma, prompting interest in immunotherapy approaches. The only FDA-approved immunotherapy in cholangiocarcinoma is pembrolizumab, an anti-PD-1 antibody, which received tissue-agnostic approval for solid tumours with microsatellite instability or mismatch repair deficiency, including cholangiocarcinoma.The response rate to PD-1 blockade monotherapy is low in unselected cases of advanced cholangiocarcinoma, underscoring the need for biomarkers of response, novel immunotherapies, and combination therapies.Immune-mediated approaches currently under investigation include combining immune checkpoint blockade with molecularly targeted therapy, local ablative therapy, chemotherapy, and other agents. Cell-based therapies, cancer vaccines, and agents targeting novel immune checkpoints, cytokines, colony stimulating factors, and the tumour microenvironment are also under development.Alt-text: Unlabelled Box

Introduction {#s0005}
============

Cholangiocarcinoma (CCA) is the most common biliary malignancy and the second most common primary hepatic malignancy after hepatocellular carcinoma (HCC). CCAs are heterogeneous biliary epithelial tumours that are classified into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes based on their anatomic location within the biliary tree. The overall incidence of CCA, particularly iCCA, has increased over recent decades. Unfortunately, the 5-year overall survival (OS) for CCA remains less than 10%.[@bb0005], [@bb0010] Surgical resection or liver transplantation following neoadjuvant chemoradiation are potentially curative treatment options for the subset of patients who present with early-stage disease.[@bb0010] However, diagnosing CCA at an early stage remains a significant challenge, and the majority of patients present with advanced stage disease.[@bb0010], [@bb0015], [@bb0020], [@bb0025]

Advances in our understanding of the immunobiology of the tumour immune microenvironment (TIME) have resulted in the advent of cancer immunotherapies that modulate the host immune response against tumours.[@bb0030] Tumours can escape the host immune attack by induction of immune checkpoints such as programmed death-1 (PD-1) and its ligand PD-L1, as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Accordingly, antibody-based therapies targeting these mediators, so called immune checkpoint blockade (ICB), unleash pre-existing immunity and have become the major focus of anticancer therapeutic interventions. ICB therapies have demonstrated durable responses in a subset of patients.[@bb0035] ICB response is associated with the TIME phenotype, with a T cell-infiltrated TIME having a higher response to ICB compared to a non-T cell infiltrated TIME.[@bb0030], [@bb0040] A T cell-infiltrated TIME displays spontaneous immune activation and is characterized by the presence of high infiltration of CD8^+^ T cells, high expression of PD-L1, chemokines and other factors implicated in T cell recruitment. A non-T cell infiltrated TIME displays immune exclusion and lacks T cells due to the absence of chemokines and activation factors involved in T cell recruitment.[@bb0030], [@bb0040] The latter phenotype also lacks T cell priming, likely due to the absence of upstream innate immune activation.

CCAs are desmoplastic tumours with a dense TIME populated by cancer-associated fibroblasts as well as immunosuppressive innate immune cells such as tumour-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). These stromal elements are essential in promoting an immunosuppressive TIME and foster CCA progression by producting cytokines and chemokines. Herein, we review the innate and adaptive host immune response to CCA and emerging immunotherapies modulating the immune system.[@bb0045]

The innate immune system in cholangiocarcinoma {#s0010}
==============================================

The liver has ample unique immunological features including the ability to induce immune tolerance as well as a robust innate immunity.[@bb0050] The liver is constantly exposed to intestinal microbial products and must have the ability to suppress inappropriate inflammatory responses while remaining alert to potential harmful stimuli such as infectious agents or cancer cells.[@bb0050] The liver's distinct immune environment includes the largest population of resident macrophages (80--90% of total body population) referred to as Kupffer cells (KCs) and an abundance of natural killer (NK) cells.[@bb0050], [@bb0055] KCs are key mediators of induction of immunological tolerance in the liver. The tolerogenic capability of the liver may be important in tumour biology as cancers may co-opt this machinery to promote immune tolerance, facilitating tumour progression. Hence, elucidating the innate immune response to CCA is essential in the effort to uncover effective immunotherapies.[@bb0060]

Macrophages in cholangiocarcinoma {#s0015}
---------------------------------

Macrophages are phagocytic innate immune cells which are extremely heterogeneous, and play an essential role in hepatobiliary malignancy.[@bb0055], [@bb0065] They represent the first line of defence against damage-associated molecular patterns expressed by cancer cells, or pathogen-associated molecular patterns.[@bb0070] Hepatic macrophages may be categorized by ontogeny as resident or recruited macrophages. Resident macrophages include yolk-sac derived KCs which have the capacity to self-renew, and a recently described population of liver capsular macrophages which are replenished from blood monocytes.[@bb0075] Recruited hepatic macrophages include circulating monocytes that differentiate into macrophages, and a reservoir of peritoneal macrophages which traffic through the capsule into the liver parenchyma.[@bb0055], [@bb0080] Polarization refers to the functional activation of macrophages. In tumour biology, TAMs are an essential component of the TIME, and are implicated in tumour immune escape.[@bb0085], [@bb0090] The terminology for TAM polarization is complex, and includes an immunosuppressive, alternatively activated, pro-tumour 'M2-like' phenotype and an antitumour, classically activated 'M1-like' phenotype.[@bb0090] TIME factors contributing to TAM plasticity include cytokines, as well as hypoxia and cancer cell-derived extracellular vesicles (EVs).[@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0085], [@bb0095] Several studies have demonstrated an association between the presence of TAMs and patient outcomes in CCA.[@bb0120] In a cohort of 39 patients with iCCA, TAM infiltration was associated with angiogenesis, increased infiltration of regulatory T cells (Treg), and poor disease-free survival.[@bb0120] The authors also demonstrated that CCA cells induce an M2-like phenotype via signal transducer and activator of transcription 3 activation.[@bb0085], [@bb0120] Similarly, a retrospective analysis employing immunohistochemistry (IHC) in 114 patients with CCA demonstrated a positive correlation between tumour-infiltrating neutrophils, TAMs, and Tregs.[@bb0125] Moreover, the presence of these immunosuppressive immune cell populations was significantly associated with poor recurrence-free survival.[@bb0125] Conflicting results have been obtained from studies assessing a link between TAM localization within the tumour and patient outcomes; one study demonstrated worse outcomes (47 patients with pCCA) and another demonstrated improved OS (88 patients with iCCA) with high infiltration of TAMs in the tumour invasive front.[@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150]

Studies investigating the mechanism of TAM-mediated CCA progression are limited. Yuan *et al*. have demonstrated that chronic liver injury induces mitochondrial dysfunction, resulting in oxidative stress and the recruitment of KCs.[@bb0155] Moreover, tumor necrosis factor (TNF) derived from KCs promotes JNK-mediated CCA proliferation and oncogenic transformation, depletion of KCs has been shown to reduce pre-malignant CCA lesions.[@bb0155] Canonical WNT signalling drives cell proliferation, and is activated in CCA.[@bb0160] Alternatively activated macrophages activate WNT signalling in CCA with consequent CCA progression.[@bb0160] Macrophage depletion in preclinical models results in inhibition of WNT signalling, and reduction in tumour growth.[@bb0160] As TAM infiltration has been associated with poor patient outcomes, it has been postulated that CCA cells may modulate the surrounding stroma to a tumour supportive immune niche. Cellular spheroids generated from CCA cells molded macrophages to a TAM phenotype with high invasive capacity.[@bb0165] TAMs isolated from resected human CCA specimens recapitulated the phenotype of the *in vitro* macrophages educated by CCA cells.[@bb0165] Although these studies have explored the mechanisms underlying TAM-mediated CCA progression, further work is needed to elucidate the mechanisms behind the pro-tumour role of macrophages in CCA.

Myeloid-derived suppressor cells in cholangiocarcinoma {#s0020}
------------------------------------------------------

MDSCs are a subset of immature myeloid cells with potent immunosuppressive function.[@bb0170] In a variety of malignancies, MDSCs accumulate in the bone marrow, peripheral blood, lymphoid tissues, and the tumour microenvironment with resultant augmentation of tumour immune evasion and immunotherapy resistance.[@bb0175] MDSCs are not an independent lineage of myeloid cells. Instead, they comprise immature myeloid cells that are pathologically activated in the setting of chronic inflammation. MDSCs inhibit cytotoxic T cells (CTLs), NK cells and other subsets via multiple antigen-specific and non-specific mechanisms, including production of arginase, inducible nitric oxide synthase (iNOS), indoleamine 2,3-dioxygenase (IDO), reactive oxygen species (superoxide, myeloperoxidase, hydroxyl peroxide, and peroxynitrite) and immunosuppressive cytokines (including transforming growth factor-beta \[TGF-β\] and interleukin \[IL\]-10).[@bb0180], [@bb0185], [@bb0190] MDSC are subdivided into monocytic and granulocytic or polymorphonuclear (PMN) subsets (M-MDSC and PMN-MDSC), that are phenotypically similar to macrophages and neutrophils, respectively, albeit biochemically and functionally distinct.[@bb0195] M-MDSC can differentiate into TAMs in the tumour immune microenvironment, while short-lived PMN-MDSCs likely overlap with immunosuppressive tumour-associated neutrophils.[@bb0200]

The majority of data regarding the role of MDSCs in hepatobiliary cancers come from HCC. Clinically, an increase in M-MDSC in peripheral blood is prognostic, and has been associated with decreased OS in HCC.[@bb0205] In murine models of HCC, MDSCs accumulate in the liver and polarize Kupffer cells to an immunosuppressive phenotype.[@bb0210], [@bb0215] MDSC-mediated effects on lymphocytes include fostering Treg development, promoting CD8+ T cell anergy, and inhibiting NK cell cytotoxicity.[@bb0220], [@bb0225], [@bb0230] Murine models of HCC suggest that depletion of PMN-MDSC may increase sensitivity to PD-L1 checkpoint inhibitor therapy.[@bb0235] However, MDSCs have been relatively unexplored in CCA. A single publication documented a significant increase in the percentage of circulating M-MDSC (CD11b^+^/CD14^+^/HLA-DR^−^) in whole blood from 17 patients with CCA compared to healthy controls. However, further characterization or functional confirmation was not carried out.[@bb0240] Therefore, additional studies are needed to characterize the contribution of MDSCs to CCA and explore their potential as a viable immunotherapeutic target.

Natural killer cells in cholangiocarcinoma {#s0025}
------------------------------------------

Preclinical and clinical studies have demonstrated that NK cell deficiency or impaired NK cell function is linked to increased incidence of a variety of malignancies. NK cells are 'ready to kill'; indeed, NK cells are able to identify and spontaneously eliminate abnormal cells such as cancer cells without prior sensitization.[@bb0245] Activated NK cells mediate tumour immunosurveillance and modulate the immune response via secretion of a large spectrum of cytokines and chemokines. NK cells also play an essential role in cancer immunoediting via secretion of interferon-gamma which induces activation of M1-like macrophages.[@bb0250] Nonetheless, it has been postulated that the predominant role of NK cells in tumour immunosurveillance might be prevention of metastasis, as NK cells are abundant in the circulation but relatively scarce in solid tumours. NK cells comprise approximately 30-40% of the total hepatic lymphocyte population; a liver resident NK cell subset with adaptive immune properties that originates from hepatic stem cells has been described.[@bb0255], [@bb0260]

Natural killer group 2D (NKG2D), an activating NK cell receptor, is involved in NK cell-mediated killing of tumour cells. Genetic variants of the NKG2D receptor impair the cytotoxic function of NK cells. Accordingly, NKG2D receptor variants have been linked to CCA development in patients with primary sclerosing cholangitis.[@bb0265] In contrast, high expression of NKG2D ligands in human CCA are associated with improved disease-free and overall patient survival, implying that treatment strategies that encourage interaction between NKG2D and its ligand may be a promising therapeutic approach in CCA.[@bb0270] Preclinical data from studies assessing therapeutic strategies that augment NK cell activity in CCA are encouraging, albeit limited. Co-culture of CCA cells with the epidermal growth factor receptor monoclonal antibody, cetuximab, and NK cells significantly enhanced CCA cell death by potentiating antibody-dependent cellular cytotoxicity.[@bb0275] Similarly, infusion of *ex vivo* expanded human NK cells into CCA xenograft mice resulted in inhibition of tumour growth.[@bb0280] Although these findings hold promise, further work is needed to investigate NK cell-based therapies in CCA.

Dendritic cells in cholangiocarcinoma {#s0030}
-------------------------------------

Dendritic cells (DCs) are antigen presenting cells (APCs) which are essential in activation of the adaptive immune response.[@bb0285] DCs are categorized broadly as classical DCs (cDCs) and plasmacytoid DCs (pDC). cDCs are highly phagocytic APCs which are replenished from bone marrow precursors.[@bb0290] cDCs initiate adaptive immune responses in secondary lymphoid organs following their interaction with antigens in peripheral tissues.[@bb0290] pDCs, although developmentally related to cDCs, are not phagocytic, and are ineffective at presenting exogenous antigens to CD4^+^ T cells. Following activation, pDCs acquire typical DC morphology and release interferon-gamma.[@bb0295]

Compared to healthy controls, patients with CCA have a significant decrease in the absolute number of peripheral blood cDCs as well as a decline in the TNFα-producing cDCs.[@bb0300] Immunohistochemical analysis has demonstrated a correlation between CD83^+^ (mature) cDCs and CD4^+^/CD8^+^ T cell infiltration at the invasive margin of cancer. Moreover, patients with an increased number of CD83^+^ cDCs at the tumour invasive margin had a lower incidence of lymph node metastasis and overall better outcomes compared to patients with a paucity of CD83^+^ cDCs.[@bb0305] As the presence of DCs confers a better patient outcome, the therapeutic potential of DC-based immunotherapies has been explored in limited preclinical and clinical studies of CCA. DCs loaded with aspartate-β-hydroxylase (ASPH), a tumour-associated cell surface protein present in a number of malignancies, induced suppression of tumour growth and metastasis, as well as increased CD3^+^ lymphocyte infiltration in an orthotopic rat model of iCCA.[@bb0310] Interestingly, the remaining tumour cells still expressed ASPH. This latter finding implies that "escape mutants" mediating tumour evasion had not developed, and additional immunizations may be necessary for optimal antitumour activity.[@bb0310] Overall, the role of DCs and various DC subsets in CCA needs to be further delineated.

Adaptive immune response in cholangiocarcinoma {#s0035}
==============================================

Tumour-infiltrating lymphocytes (TILs) are a highly heterogeneous population that includes CD8^+^ cytotoxic T cells, CD4^+^ T helper cells, Tregs and B lymphocytes.[@bb0315], [@bb0320], [@bb0325] TILs are essential in cancer immune surveillance and in the elimination of tumour cells. Adaptive immune response components decrease with CCA progression.[@bb0330] Conversely, an increase in CD8^+^ TILs is associated with improved overall patient survival.[@bb0330], [@bb0335], [@bb0340], [@bb0345] Intratumoural CD4^+^/CD8^+^ TILs are found in 57--68% of CCA.[@bb0350], [@bb0355] Based on immunohistochemical analyses, CD8^+^ TILs appear to be the primary TILs within the tumour tissue whereas CD4^+^ cells are the predominant lymphocyte population in the peritumoural area.[@bb0305], [@bb0360] The presence of mature DCs at the invasive margin of CCAs correlates significantly with CD8^+^ and CD4^+^ T cell infiltration in the tumour region and improved patient survival.[@bb0305] However, the role of CD4^+^ TILs in the tumour immune response is controversial. Although, CD4^+^ TILs can suppress tumour growth through cytokine secretion, a low CD4/CD8 ratio is associated with a better prognosis in colorectal carcinoma, suggesting an immunosuppressive effect of CD4^+^ TILs.[@bb0365], [@bb0370] However, in a cohort of 306 resected human CCA specimens immunohistochemical analysis demonstrated that an increase in tumour-infiltrating CD4^+^ T cells was associated with longer patient survival.[@bb0330] Interplay between components of the innate immune system and TILs can impact the antitumour immune response. Patients with CCA and high tumour tissue expression of CD15, a carbohydrate epitope expressed on neutrophils, have shorter OS and disease-free survival.[@bb0375] Accordingly, an elevated neutrophil-lymphocyte ratio (NLR) is associated with a higher percentage of PD-1^+^ TILs and lower percentage of IFN-γ^+^ TILs.[@bb0380] In a cohort of 102 patients with iCCA, who had undergone surgical resection, an elevated NLR was an independent predictor for poor OS and recurrence-free survival.[@bb0380] A subset of CCAs are immune 'hot' tumours with increased infiltration of TILs and high PD-L1 expression ([Fig. 1](#f0005){ref-type="fig"}). Immunohistochemical analysis of human resected specimens (n = 99, 58 iCCA and 41 pCCA) demonstrated a significant correlation between PD-L1 expression and a higher density of CD3^+^ TILs.[@bb0350] PD-L1 expression in CCA varies between different series, and has been reported to be 55--72%.[@bb0350], [@bb0385], [@bb0390] Moreover, PD-L1 is expressed predominantly on immune cells in CCA (46--63%)[@bb0350], [@bb0390] rather than cancer cells (9--23%).[@bb0350], [@bb0355], [@bb0395]Fig. 1The evolving tumour immune microenvironment of CCA.T cell-infiltrated or immune 'hot' CCAs have increased CD8^+^ T cell infiltration with enhanced interferon γ and granzyme B activity, antitumour DCs and NK cells, increased immune checkpoint molecules such as PD-1 and its ligand PD-L1, and enhanced responsiveness to ICB. Non-T cell-infiltrated or immune 'cold' CCAs are devoid of CD8^+^ T cells and have a preponderance of immunosuppressive cells such as M2-like TAMs, MDSCs, and tolerogenic DCs. These tumours are generally poorly responsive to ICB. CAF, cancer-associated fibroblast; CCA, cholangiocarcinoma; DC, dendritic cell; ICB, immune checkpoint blockade; MDSC, myeloid-derived suppressor cell; NK, natural killer; PD-1, programmed death-1; PD-L1, programmed death ligand 1; TAM, tumour-associated macrophage; TMB, tumour mutational burden.Fig. 1

High PD-L1 expression has been linked to an increase in apoptotic TILs.[@bb0400] FoxP3^+^ TILs have also been implicated in CD8^+^ T cell apoptosis and consequent tumour immune escape in CCA.[@bb0405] Indeed, downregulation of FoxP3 results in the attenuation of CCA proliferation and invasion, as well as enhanced tumour cell apoptosis.[@bb0405] Although CD20^+^ B cells represent a minor proportion of the total TIL population in CCA, their presence has been linked to a favourable prognosis in CCA.[@bb0330], [@bb0360] Collectively, our knowledge of the adaptive immune system in CCA is based primarily on small retrospective studies utilizing immunohistochemical analysis. Future studies should employ sophisticated immunoprofiling techniques such as mass cytometry to elucidate the role of the adaptive immune system in CCA.

Immunotherapy clinical trials in cholangiocarcinoma {#s0040}
===================================================

Standard of care {#s0045}
----------------

The standard first-line treatment for advanced biliary tract cancers (BTCs), including cholangiocarcinoma, is gemcitabine and cisplatin combination chemotherapy. This regimen modestly increased survival, with a median OS of 11.7 months in patients treated with gemcitabine/cisplatin, compared to 8.1 months for those treated with gemcitabine alone in a phase III trial.[@bb0410] The use of other gemcitabine or fluoropyrimidine-based chemotherapy regimens is supported by phase II trials. An open-label, single-arm, phase II clinical trial demonstrated prolonged median progression free survival (PFS) (11.8 months) and median OS (19.2 months) in patients with advanced BTC (n = 62) treated with nab-paclitaxel plus gemcitabine-cisplatin compared to historical controls treated with gemcitabine-cisplatin alone.[@bb0415] However, given the limited efficacy of these regimens, there is a pressing need to develop additional therapeutic approaches.

Immune checkpoint blockade {#s0050}
--------------------------

Immune checkpoint inhibitors are designed to overcome inhibitory receptors on CTLs to promote an antitumour immune response. Agents targeting the PD-1 and CTLA-4 pathways have been approved in multiple malignancies, and in some cases provide durable responses. However, even among immunogenically 'hot' tumour types such as melanoma and non-small cell lung cancer, response to ICB is variable. Current research priorities in CCA and other tumour types include determining biomarkers of response, and developing combination strategies to improve response rates and circumvent immunologic tolerance and resistance.[@bb0420] One established predictor of response to ICB is the neo-antigen burden of a tumour, which may be secondary to carcinogen exposure, oncoviral integration, APOBEC gene expression, microsatellite instability due to mismatch repair deficiency (MSI-high/MMR-deficient), or other factors. In a comprehensive molecular analysis, approximately 6% of biliary cancers were hypermutated (with a tumour mutation rate ≫11.13/Mb), including 2% that were MMR-deficient.[@bb0425] This suggests that a subset of CCAs may be primed to respond to ICB ([Fig. 2](#f0010){ref-type="fig"}). Indeed, ICB has shown promise in patients with MSI-high/MMR-deficient CCA. The efficacy of pembrolizumab, a monoclonal anti-PD-1 antibody, was evaluated in a prospective manner in 86 patients with advanced MSI-high/MMR-deficient cancers including CCA (n = 4).[@bb0430] The disease control rate (DCR) in patients with CCA was 100%; 1 patient had complete response (CR) and 3 had stable disease.[@bb0430] An analysis of 5 uncontrolled, single-arm, open-label trials of pembrolizumab (KEYNOTE-012, 016, 028, 158, and 164) included 149 patients with MSI-high/MMR-deficient tumours (90 metastatic colorectal cancers and 59 other tumour types, including 11 BTCs). The objective response rate (ORR, sum of CR and partial response \[PR\]) was 39.6%, with 78% of those having a duration of response of 6 months or longer. Out of 11 patients with BTC, 3 (27%) had a response, with duration of response ranging from 11.6 to 19.6 months.[@bb0435] These encouraging results led to the accelerated food and drug administration (FDA) approval of pembrolizumab for the first tissue/site agnostic indication in MSI-high/MMR-deficient tumours ([www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm](http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm){#ir0035}). Taken together, these analyses suggest that PD-1 blockade may be effective for advanced MSI-high/MMR-deficient CCA that has progressed on standard therapies.Fig. 2Schematic representation of therapeutic strategies for immune 'hot' CCA.The targets of immunotherapies currently under investigation in CCA that may be beneficial in immune 'hot' CCA are represented schematically. CCA, cholangiocarcinoma; CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DC, dendritic cell; NK, natural killer; PD-1, programmed death-1; PD-L1, programmed death ligand 1; TAM, tumour-associated macrophage.Fig. 2

Tumour expression of PD-L1 is a biomarker for response to ICB in other tumour types, but has not been fully explored in CCA. KEYNOTE-028 (NCT02054806) was an open-label, phase I basket trial with 20 different solid tumour cohorts, including BTCs.[@bb0385] All selected patients had positive PD-L1 expression, defined by expression on ≫1% of tumour cells by IHC-based assay. The BTC cohort included 23 patients, with an ORR of 17% (4 of 23), including 1 CR and 3 PR; an additional 3 patients had stable disease. Median PFS was 1.8 months, and median OS was 6.2 months. Multiple biomarkers were evaluated, including expression of an 18-gene T cell-inflamed profile, PD-L1 expression, and tumour mutational burden (TMB). All 3 were correlated with higher response rates in the study population overall, and the highest response rates were found among patients with both elevated TMB and a second biomarker (PD-L1 expression or T cell-inflamed gene expression profile).[@bb0385] Although biomarker data was not presented for the biliary cancer cohort specifically, these results suggest that a combination of biomarkers can identify patients most likely to respond to ICB.

These encouraging results led to a follow-up trial with an expansion cohort, KEYNOTE-158 (NCT02628067), the largest study to date of ICB in BTCs. This is an ongoing phase II, single-arm, open-label trial of pembrolizumab in multiple advanced cancers. An interim report was presented in 2018 with data from 104 patients with BTC.[@bb0440] The ORR was only 5.8%, including 6 PR and zero CR, with an additional 17 patients (16%) having stable disease. The duration of response (DoR) ranged from 6.2 to ≫15 months (in 2 patients), with the median DoR not reached. Interestingly, PD-L1 expression was not predictive of response. The cohort contained 61 patients with PD-L1 positive tumours, and 31 patients without PD-L1 expression. Although ORR was slightly higher in the PDL-1 positive group (6.6% *vs.* 2.9%), there were no significant differences in median PFS (1.9 *vs.* 2.1 months) or OS (7.2 *vs.* 9.6 months).[@bb0440] In this cohort, none of the evaluated patients had MSI-high tumours. This limited response to ICB monotherapy in an unselected cohort of advanced biliary cancer further emphasizes the need for biomarkers (that identify patients likely to respond), and combinatorial treatment strategies (that overcome limited antitumour responses in CCA).

Immune checkpoint blockade -- combination therapies {#s0055}
---------------------------------------------------

Given the limitations of ICB monotherapy, there is tremendous interest in developing combination immunotherapy strategies. Such strategies include dual ICB as well as ICB combined with another immunomodulatory agent, molecular targeted therapy, cytotoxic chemotherapy, or local therapy ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}).[@bb0445] The premise of dual ICB is that blocking a single checkpoint may not be sufficient to activate CTLs. Although combining CTLA-4 and PD-1 blockade has increased efficacy, it has also increased adverse events (AE) in melanoma.[@bb0450], [@bb0455] At least 2 early phase trials of dual CTLA-4 and PD-1 blockade are ongoing in advanced solid tumours, including CCAs (NCT02834013 and NCT01938612). Interim results from an open-label phase I/II study of durvalumab plus tremelimumab in patients with HCC and BTC who had progressed on prior therapy (NCT02821754) were relatively disappointing for BTC. None of the patients in the BTC cohort had PR or CR, and only 5 (42%) had stable disease. The median PFS was 3.1 months and OS was 5.5 months, while multiple grade 3/4 treatment-related AEs were reported.[@bb0460] Efficacy in this study may have been hampered by inclusion of an unselected BTC population. However, given the increased risk for adverse events and limited efficacy of combination PD-1/CTLA-4 blockade, there is substantial interest in investigating alternative combination immunotherapies.Table 1Ongoing ICB-based clinical trials in cholangiocarcinoma.Table 1InterventionTrial typePopulation (\# participants, estimated enrollment)[ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0010} IdentifierImmune checkpoint blockade monotherapy Pembrolizumab (anti-PD-1 antibody)Phase II, single arm, open label;\
Phase II, non-randomized, open label;\
Phase Ib, single arm, open label;\
Phase II, single arm, open label;\
Prospective observational cohortAdvanced, refractory BTC (33 pts);\
Microsatellite unstable cancers, including BTC (171 pts);\
PD-L1 positive cancers, including BTC (477 pts);\
Advanced, refractory cancers, including BTC (1,350 pts);\
HCC or BTC (100 pts)NCT03110328;\
NCT01876511;\
NCT02054806;\
NCT02628067;\
NCT03695952 Nivolumab (anti-PD-1 antibody)Phase II, single arm, open label;\
Phase II, non-randomized, open label\
Prospective observational cohortAdvanced, refractory BTC (52 pts);\
Advanced, refractory cancers with MMR deficiency (6,452 pts);\
HCC or BTC (100 pts)NCT02829918;\
NCT02465060;\
NCT03695952 Durvalumab (anti-PD-L1 antibody)Phase I, non-randomized, open labelAdvanced solid tumours, including BTC (269 pts)NCT01938612 Toripalimab (anti-PD-1 antibody)Phase Ib/II, single arm, open labelHCC or iCCA, eligible for resection (20 pts)NCT03867370 Atezolizumab (anti-PD-L1 antibody)Phase II, Non-randomized, open labelAdvanced, refractory solid tumours, including BTC, elevated tTMB (765 pts)NCT02091141Dual immune checkpoint blockade Nivolumab + Ipilimumab (anti-CTLA-4 antibody)Phase II, single arm, open label;\
Phase II, randomized, open labelAdvanced, refractory solid tumours including BTC (707 pts);\
Unresectable, untreated BTC (64 pts)NCT02834013;\
NCT03101566 Durvalumab + Tremelimumab (anti-CTLA-4 antibody)Phase I, non-randomized, open labelAdvanced, refractory, biopsiable solid tumours, including BTC (269 pts)NCT01938612Immune checkpoint blockade plus local ablative therapy Durvalumab + Tremelimumab + TACE, RFA, or cryoablationPhase II, non-randomized, open labelUnresectable, refractory HCC or BTC (90 pts)NCT02821754 Tremelimumab + RFAPhase I, non-randomized, open labelUnresectable, refractory HCC or BTC, eligible for RFA (61 pts)NCT01853618 Pembrolizumab + SBRT *vs.* GEMCIS chemotherapyPhase II, randomized, open labelUnresectable, untreated iCCA, eligible for radiotherapy (184 pts)NCT03898895 Durvalumab + Tremelimumab + radiation therapyPhase II, single arm, open labelUnresectable HCC or BTC (70 pts)NCT03482102Immune checkpoint blockade plus chemotherapy Durvalumab + Tremelimumab + GEM or GEMCIS *vs.* GEMCIS chemotherapyPhase II, randomized, open labelUntreated BTC (63 pts)NCT03473574 Durvalumab + Tremelimumab + GEMCIS chemotherapyPhase II, single arm, open labelunresectable, untreated BTC (31 pts)NCT03046862 Durvalumab + Tremelimumab + PaclitaxelPhase II, randomized, open labelRecurrent or advanced, refractory BTC (102 pts)NCT03704480 Durvalumab + GEMCIS *vs.* GEMCIS chemotherapyPhase III, randomized, double-blind, placebo-controlledUnresectable, untreated BTC (474 pts)NCT03875235 Durvalumab + GuadecitabinePhase Ib, single arm, open labelUnresectable, refractory HCC, PDAC, or BTC excluding ampullary (90 pts)NCT03257761 Camrelizumab (anti-PD-1 antibody) + GEMOX chemotherapyPhase II, single arm, open labelAdvanced CCA (38 pts)NCT03486678 Camrelizumab + Apatinib (VEGFR2 inhibitor), FOLFOX4 or GEMOX chemotherapyPhase II, non-randomized, open labelAdvanced, untreated HCC or BTC (152 pts)NCT03092895 Pembrolizumab + CAPOX chemotherapyPhase II, single arm, open labelUnresectable, refractory, biopsiable BTC (19 pts)NCT03111732 Pembrolizumab + GEMCISPhase II, single arm, open labelUnresectable, untreated BTC (50 pts)NCT03260712 Toripalimab + GemcitabinePhase II, single arm, open labelAdvanced BTC (40 pts)NCT03796429 Nivolumab + GEMCISPhase I/II, single arm, open label;\
Phase II, randomized, open labelUnresectable BTC (30 pts);\
Unresectable, untreated BTC (64 pts)NCT03311789;\
NCT03101566 nivolumab + nal-irinotecan + 5-fluorouracil + leucovorinPhase I/II, single arm, open labelUnresectable, refractory BTC (40 pts)NCT03785873 KN035 (anti-PD-L1 antibody) + GEMOX *vs.* GEMOX chemotherapyPhase III, randomized, open labelUnresectable, untreated BTC (390 pts)NCT03478488Immune checkpoint blockade plus molecularly targeted therapy Pembrolizumab + pemigatinib (FGFR1-3 inhibitor)Phase I/II, single arm, open labelAdvanced, refractory solid tumours, including CCA, with genetic alteration of *FGF* or *FGFR* genes (325 pts)NCT02393248 Nivolumab + FT-2102 (mutant IDH1 inhibitor)Phase I/II, non-randomized, open labelSelected solid tumours, including BTC, with *IDH1* mutations (200 pts)NCT03684811 Atezolizumab + cobimetinib (MEK inhibitor)Phase II, randomized, open labelUnresectable, refractory BTC (82 pts)NCT03201458 Durvalumab + tremelimumab + selumetinib (MEK inhibitor)Phase I, non-randomized, open labelAdvanced, refractory solid tumours, including BTC (58 pts)NCT02586987 Nivolumab + rucaparib (PARP inhibitor)Phase II, single arm, open labelAdvanced, refractory BTC (35 pts)NCT03639935 TPST-1120 (PPARα antagonist) + Nivolumab, docetaxel chemotherapy or cetuximab (anti-EGFR antibody)Phase I, non-randomized, open labelAdvanced solid tumours, including CCA (338 pts)NCT03829436 Pembrolizumab + XL888 (Hsp90 inhibitor)Phase I, single arm, open labelAdvanced, refractory GI cancers, including CCA (50 pts)NCT03095781 Atezolizumab + DKN-01 (anti-Dickkopf-1 antibody)Phase I, single arm for BTC, open labelNon-operable, refractory oesophageal and BTC (123 pts)NCT03818997 Nivolumab, pembrolizumab or chemotherapy + TRK-950 (monoclonal antibody targeting a proprietary tumour antigen)Phase I, non-randomized, open labelAdvanced solid cancers, including CCA (36 pts)NCT03872947[^1]Table 2Ongoing immunotherapy clinical trials targeting the immune microenvironment in cholangiocarcinoma.Table 2InterventionTrial typePopulation (\# participants, estimated enrolment)[ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0020} IdentifierImmune microenvironment targeted therapy Interferon alpha + G-CSF + fluorouracil + hydroxyureaPhase II, single arm, open labelUnresectable GI cancers, including BTC (60 pts)NCT00019474 INCB001158 (arginase inhibitor) + FOLFOX, GEMCIS or paclitaxel chemotherapyPhase I/II, non-randomized, open labelAdvanced solid tumours including BTC (249 pts)NCT03314935 Recombinant interleukin-12 + trastuzumab (anti-HER2 antibody)Phase I, single arm, open labelAdvanced, refractory, HER2-expressing solid tumours, including BTC (15 pts)NCT00004074 CDX-1140 (CD40 agonist antibody) +/- CDX-301 (dendritic cell growth factor)Phase I, non-randomized, open labelAdvanced, refractory, biopsiable cancers, including CCA (180 pts)NCT03329950 ABBV-368 (OX40 agonist antibody) +/- ABBV-181 (anti-PD-1 antibody)Phase I, non-randomized, open labelAdvanced solid cancers, including CCA (170 pts)NCT03071757Immune microenvironment targeted therapy plus immune checkpoint blockade Peginterferon alpha-2b + PembrolizumabPhase II, single-arm, open labelAdvanced, refractory, biopsiable CCA (44 pts)NCT02982720 Sargramostim (GM-CSF) + PembrolizumabPhase II, single arm, open labelAdvanced BTC (42 pts)NCT02703714 Cabiralizumab (anti-CSF1R antibody) + NivolumabPhase II, randomized, open labelResectable, biopsiable BTC (16 pts)NCT03768531 M7824 (anti-PD-L1/TGFbetaRII fusion protein)Phase II, single arm, open labelAdvanced, refractory BTC (141 pts)NCT03833661 Entinostat (histone deacetylase inhibitor) + NivolumabPhase II, non-randomized, open labelAdvanced, untreated CCA or PDAC (54 pts)NCT03250273 Ramucirumab (anti-VEGFR-2 antibody) + PembrolizumabPhase I, single arm, open labelSelect advanced, refractory, biopsiable cancers, including BTC (155 pts)NCT02443324 Lenvatinib (VEGFR2 inhibitor) + PembrolizumabPhase II, single arm, open label;\
Phase II, single arm, open labelAdvanced, refractory, primary liver cancer or BTC (50 pts);\
Selected advanced, refractory solid tumours, including BTC (180 pts)NCT03895970;\
NCT03797326 Anlotinib hydrochloride (multi-RTK and VEGFR2-3 inhibitor) + TQB2450 (Anti-PD-L1 antibody)Phase Ib/II, single arm, open labelAdvanced, refractory BTC or HCC (60 pts)NCT03825705 Avelumab (anti-PD-L1 antibody) with Regorafenib (multi-RTK and VEGFR 2/3 inhibitor)Phase I/II, non-randomized, open labelAdvanced, refractory digestive tumours, not MMR-deficient (212 pts)NCT03475953 pegylated recombinant human hyaluronidase PH20 + atezolizumab + GEMCIS chemotherapyPhase I, randomized, open labelAdvanced, untreated BTC (70 pts)NCT03267940[^2]

Beyond CTLA-4 and PD-1, there are a host of additional immune checkpoints which may be modulated to promote an antitumour immune response, including the inhibitory receptors LAG-3, TIM-3, TIGIT, and VISTA, and activating receptors OX40, GITR, 4-1BB, and CD40 ligand.[@bb0445] Preclinical and clinical data regarding these checkpoints are far less mature, but there is early data from melanoma and renal cell carcinoma suggesting some clinical effect of LAG-3 inhibitors.[@bb0465], [@bb0470] Clinical trials are currently underway targeting CD40 (NCT03329950) and OX40 (NCT03071757) as single agent or combination therapies in advanced cancers including CCA.

Several cytokine-targeted therapies have been combined with ICB. Granulocyte--macrophage colony-stimulating factor (GM-CSF), encoded by the *CSF2* gene, is a cytokine that can increase antigen presentation and cytotoxic T cell function. Systemic administration of GM-CSF in combination with ICB prolonged OS compared to ICB alone in a phase II trial in melanoma.[@bb0475] Interim analysis of an open-label, single-arm, phase II trial of pembrolizumab plus GM-CSF in CCA (n = 27; 70% iCCA) showed an ORR of 21% (5 of 24 patients), including PR in 4 patients with microsatellite stable (MSS) tumours. Two additional MSS patients had durable declines in CA19-9 for ≫11 months.[@bb0480]

Interferon-alpha-2 is a cytokine that increases antigen presentation via upregulation of host MHC class I and II molecules, leading to increased tumour infiltration of dendritic and T cells.[@bb0485] Systemic administration of pegylated interferon-alpha-2b is approved for use in the adjuvant setting for treatment of melanoma.[@bb0490] In CCA, clinical trials evaluating interferon-alpha-2 with pembrolizumab (NCT02982720) or in combination with chemotherapy (NCT00019474) are currently ongoing. Other ongoing trials in CCA featuring immunomodulators include a fusion protein designed to inhibit PD-L1 and TGF-β, an immunosuppressive cytokine (NCT03825705),[@bb0495] and recombinant IL-12, a pro-inflammatory cytokine, combined with HER2 targeted therapy (NCT00004074; [Table 2](#t0010){ref-type="table"}).

Combination of immune checkpoint blockade and microenvironment-directed therapy {#s0060}
-------------------------------------------------------------------------------

Agents targeting the tumour microenvironment have also been combined with ICB. The vascular endothelial growth factor (VEGF) pathway mediates tumour angiogenesis, growth, and metastasis. VEGF receptor (VEGFR) inhibitors are approved for treatment of multiple cancers, including HCC, but have shown limited activity as monotherapy in CCA.[@bb0500], [@bb0505] KEYNOTE-098 (NCT02443324) is an open-label, phase I trial of pembrolizumab combined with ramucirumab, an anti-VEGFR-2 antibody, which recruited 26 patients with biliary cancer (42% iCCA).[@bb0510] Of 24 evaluable patients, only 1 patient had PR (4%) while an additional 9 patients had stable disease, and no patients had CR. Median PFS was 1.6 months, and median OS 6.4 months. Overall, there was no response to this combination compared to historical controls. Of note, PD-L1 positive patients had no change in PFS, but had improved OS compared to patients with PD-L1 negative disease (11.3 *vs.* 6.1 months). Although these data support PD-L1 as a biomarker for ICB response, the small sample size and the lack of significant difference in outcomes in PD-L1 positive patients reported for KEYNOTE-158 suggests that further studies are necessary. At least 3 additional ongoing trials are evaluating the combination of VEGFR blockade and ICB ([Table 2](#t0010){ref-type="table"}).

CCAs are characterized by a desmoplastic stroma with dense extracellular matrix (ECM). Hyaluronidase is an enzyme that breaks down hyaluronic acid in the ECM. In pancreatic cancer, which is similarly desmoplastic, an interim analysis of a phase II trial showed that PEGylated recombinant human hyaluronidase (PEGPH20) increased ORR and PFS.[@bb0515] This agent is now being evaluated in combination with ICB and chemotherapy in CCA (NCT03267940).

Combination of immune checkpoint blockade and molecular targeted therapy {#s0065}
------------------------------------------------------------------------

Integrative genomic analysis of BTCs has identified recurrent genetic alterations which may be amenable to targeted therapy.[@bb0520] A tantalizing rationale for combining targeted therapies and immunotherapies is that molecular targeted therapies can produce significant but often short-lived responses in susceptible tumours, which could theoretically be prolonged with induction of an effective antitumour immune response. A pan-cancer analysis of tumour mutational burden and specific targetable mutations in The Cancer Genome Atlas dataset suggested that 9% of cancers could be amenable to combined molecular and immune-targeting therapy.[@bb0525] There are several ongoing human clinical trials evaluating the combination of ICB with a variety of targeted therapies including inhibitors of FGFR, mutant IDH, MEK, PARP, PPAR-alpha, and HSP90 (summarized in [Table 1](#t0005){ref-type="table"}).

Combination of immune checkpoint blockade and local ablative therapy {#s0070}
--------------------------------------------------------------------

Radiation and other local ablative techniques are tumouricidal. Thus, they potentially increase presentation and immune recognition of tumour neoantigens that are released by cell death, providing a rationale for the combination with ICB. NCT01853618 was an open-label, phase I study of tremelimumab (anti-CTLA4 antibody) with radiofrequency ablation in 20 patients with advanced biliary cancer. Among 16 patients with evaluable disease, 2 (13%) had PR lasting 8.0 and 18.1 months, respectively and 5 (31%) had stable disease. The median PFS was 3.4 months, and the median OS was 6.0 months. Interestingly, this study included assays for the assessment of effective tumouricidal immune responses, including expansion of CD8+ T cells with an activated phenotype and expansion of the T cell repertoire. Although conclusions are limited from this small study, there was some correlation between markers of immune activation and clinical response (HLA-DR+).[@bb0530]

Combination of immune checkpoint blockade and cytotoxic chemotherapy {#s0075}
--------------------------------------------------------------------

Chemotherapy can also increase tumour neo-antigen release by direct tumour cell killing, and alters TIME through cytotoxicity of immune subsets. MDSCs can be eliminated by chemotherapy, providing a rationale for combining cytotoxic chemotherapy with ICB or other immunotherapy.[@bb0535], [@bb0540] At least 14 clinical trials are ongoing in this category, none have yet reported interim results ([Table 1](#t0005){ref-type="table"}).

Macrophage and myeloid-directed immunotherapies {#s0080}
-----------------------------------------------

Given the importance of macrophages and MDSCs in shaping tumour immunity, there is great interest in targeting these cell types, particularly in combination with ICB.[@bb0545], [@bb0550] TAMs depend upon trophic support from macrophage colony-stimulating factor (M-CSF), encoded by the *CSF1* gene, which signals through the myeloid CSF1 receptor (CSF1R). Inhibition of the CSF1/CSF1R axis leads to TAM depletion, enhanced CTL function and improved tumour response to chemotherapy or ICB in multiple preclinical models, although this has not been investigated in CCA specifically.[@bb0555], [@bb0560] Initial results of the phase I, first-in-human study of combination CSF1R and PD-1 blockade in pancreatic cancer (NCT02526017), another highly desmoplastic tumour type with low ICB monotherapy response rates, showed a promising ORR of 10%. However, 43% of patients had grade 3-5 treatment-related AEs attributed to cabiralizumab.[@bb0565] Based on these results, combined treatment with cabiralizumab and nivolumab is currently being assessed for BTC in a phase II trial (NCT03768531). Alternative therapeutic strategies target the recruitment, polarization, and activity of TAMs and MDSCs. Inhibiting chemokine receptors (CCR2, CCR5, and CXCR2 *etc*.) to prevent recruitment of TAMs and MDSCs to the TIME is under investigation in pancreatic cancer and other tumour types, but has not yet been explored in BTC. CD40 agonists under clinical investigation in CCA (NCT03329950) are known to modify macrophage polarization in addition to their effects on adaptive immunity.[@bb0570], [@bb0575] The histone deacetylase inhibitor entinostat was shown to inhibit MDSC activity and increase the efficacy of PD-1 blockade in preclinical models of lung and renal cell cancer.[@bb0580] This combination is currently under investigation in a phase II clinical trial of advanced CCA and pancreatic cancer (NCT03250273). INCB001158 is an arginase inhibitor designed to inhibit the activity of MDSCs,[@bb0585] and is currently being evaluated in combination with chemotherapy (FOLFOX, gemcitabine/cisplatin, or paclitaxel) in a phase I/II study of advanced solid tumours including CCA (NCT03314935).

Adoptive cell therapy {#s0085}
---------------------

As the response to ICB in CCA has been subpar, it is possible that these are immunologically "cold" tumours that lack a substantial tumour-reactive T cell population. Adoptive cell therapy using CTLs or NK cells attempts to overcome this limitation ([Fig. 3](#f0015){ref-type="fig"}), with encouraging early results. In a single patient with metastatic CCA, adoptive transfer of TILs enriched for a CD4^+^ T helper 1 population of cells that recognized a tumour-specific mutation resulted in PR lasting 13 months.[@bb0590] A single patient with metastatic CCA was treated with subsequent infusions of CAR T cells targeting EGFR and CD113, with partial responses to each infusion (8.5 and 4.5 months respectively, although complicated by toxicities).[@bb0595] DC-based adjuvant immunotherapy was investigated in a small study of 62 iCCA undergoing surgical resection. Patients who received autologous tumour lysate pulsed DCs plus *ex vivo* activated T cell transfer following surgery had improved median PFS and OS (18.3 and 31.9 months, respectively) compared to patients who underwent surgery alone (7.7 and 17.4 months, respectively).[@bb0600] These results indicate that adoptive cell therapy could generate durable antitumour responses. Multiple clinical trials assessing the antitumour efficacy of adoptive T cell transfer in solid organ malignancies including CCA are ongoing ([Table 3](#t0015){ref-type="table"}).Fig. 3Schematic representation of therapeutic strategies for immune 'cold' CCA.The targets of immunotherapies currently under investigation in CCA that may be beneficial in immune 'cold' CCA are represented schematically. CAF, cancer-associated fibroblast; CCA, cholangiocarcinoma; CTL, cytotoxic T lymphocyte; DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-2, interleukin-2; IL-12, interleukin-12; MDSC, myeloid-derived suppressor cell; NK, natural killer; PEG-INFγ, PEG-interferon γ; TAM, tumour-associated macrophage; TGF-β, transforming growth factor-β; VEGFR, vascular endothelial factor receptor.Fig. 3Table 3Ongoing cell-based and vaccine immunotherapy clinical trials in cholangiocarcinoma.Table 3InterventionTrial typePopulation (\# participants, estimated enrolment)[ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0030} IdentifierAdoptive cell therapy Autologous central memory T cell therapy + radiotherapy or chemotherapyPhase II, randomized, open labeliCCA after radical resection with CR (20 pts)NCT03820310 Autologous CD8+ T-cell therapy + pembrolizumabPhase I, single arm, open labelAdvanced GI malignancies, including CCA (40 pts)NCT02757391 Autologous tumour infiltrating lymphocytes (TIL)Phase II, single arm, open labelUnresectable, refractory BTC (59 pts)NCT03801083 Autologous TIL + pembrolizumab + adesleukin (recombinant IL-2) + conditioning chemotherapyPhase II, non-randomized, open labelSelected metastatic, refractory cancers including CCA (332 pts)NCT01174121 Autologous MUC-1 CAR T-cell therapy + fludarabine/cyclophosphamidePhase I/II, single arm, open labelMUC-1 positive iCCA (9 pts)NCT03633773 Autologous Anti-CEA CAR T-cell therapyPhase I, single arm, open labelAdvanced, refractory, CEA+ cancer including BTC (not specified)NCT00004178 Allogeneic NK cell therapyPhase I, single arm, open labelAdvanced, refractory BTC (9 pts)NCT03358849 Autologous cytokine-induced NK cells + RFA *vs.* RFAPhase II/III, non-randomized, single blindUnresected CCA, without extrahepatic metastasis (50 pts)NCT02482454Vaccine and DC-based therapies Autologous dendritic cells pulsed with CEA RNAPhase I, single arm, open labelMetastatic, refractory, CEA-expressing cancers, including BTC (24 pts)NCT00004604 Autologous dendritic cells infected with fowlpox vector encoding CEA and costimulatory molecules (fowlpox-CEA-TRICOM)Phase I, single arm, open labelAdvanced, CEA-expressing cancers, including BTC (14 pts)NCT00027534 Recombinant fowlpox-CEA-TRICOM vaccine + sargramostim (GM-CSF) or recombinant fowlpox-GM-CSF vaccinePhase I, single arm, open labelAdvanced, CEA-expressing cancers, including BTC (48 pts)NCT00028496 Oral vaccine V3-X (pooled, inactivated CCA antigens)Phase I/II, single arm, open labelCCA with elevated CA19-9 (20 pts)NCT03042182 Attenuated oncolytic vaccinia virus encoding RUC-GFPPhase I, single arm, open labelAdvanced solid cancers, including CCA (36 pts)NCT02714374DNA vector encoding E-PRA and E-PSM peptidesPhase I, single arm, open labelAdvanced solid cancers, including BTC (12 pts)NCT00423254Other viral and bacterial vectors Oncolytic adenovirus encoding immunostimulatory TMZ-CD40L and 4-1BBLPhase I/II, single arm, open labelSelected advanced solid tumours, including BTC (50 pts)NCT03225989 Attenuated Salmonella Typhimurium expressing IL-2Phase I, single arm, open labelAny solid tumour, including BTC, with liver involvement or metastasis (22 pts)NCT01099631[^3]

Other immunotherapeutic strategies {#s0090}
----------------------------------

Other immunotherapeutic strategies of interest in CCA include peptide or DC-based vaccines, oncolytic viruses, and attenuated bacteria-based therapies. Peptide and DC-based vaccines are designed to increase antigen presentation and T cell priming in immunologically "cold" tumours, while viral and bacterial vectors simultaneously lyse tumour cells, increase antigen presentation, and stimulate a T cell response ([Fig. 3](#f0015){ref-type="fig"}). Peptide-based cancer vaccines have been designed to target immunogenic and tumour-associated antigens.[@bb0605] Several small, early phase studies of peptide vaccines targeting proteins such as Wilms tumour 1 (WT1) and mucin 1 (MUC1) have shown limited clinical efficacy in CCA to date.[@bb0610], [@bb0615], [@bb0620], [@bb0625] DC-based therapy was FDA-approved in metastatic prostate cancer after showing a modest benefit in OS.[@bb0630] DC-based therapies have been investigated in CCA.[@bb0635] A retrospective analysis of 65 patients with BTC treated with DCs pulsed with peptides from WT1, MUC1 or both, showed adequate safety and a median survival of 7.2 months following vaccination.[@bb0640]

Talimogene laherparepvec is an oncolytic viral therapy that is FDA-approved for metastatic melanoma. It consists of a modified HSV with tumour-selective replication and GM-CSF overexpression, and it is delivered intratumourally.[@bb0645] In CCA, preclinical studies have attempted to identify viral vectors capable of tumour-cell selective replication and lysis.[@bb0650], [@bb0655], [@bb0660] An oncolytic adenovirus encoding immunostimulatory transgenes is currently being assessed in a clinical trial in solid tumours including CCA (NCT03225989; [Table 3](#t0015){ref-type="table"}). There is an intriguing preclinical rationale behind the use of live, attenuated bacterial vectors, as they exhibit tropism for the hypoxic tumour microenvironment and the ability to stimulate innate and adaptive immune responses. However, there are significant safety concerns with this approach, and no therapies are currently FDA-approved.[@bb0665] NCT01099631 is an ongoing trial in patients with metastatic liver cancer including biliary cancer, treated with attenuated salmonella expressing IL-2.

Future perspectives {#s0095}
===================

The prevailing knowledge on the immunobiology of CCA is based primarily on IHC analyses. Future studies should employ sophisticated techniques such as mass cytometry and single cell transcriptomics to delineate the role of innate and adaptive immune cell subsets in CCA progression. In view of the subpar response rates to ICB monotherapy in CCA, effective combination immunotherapeutic strategies which harness the innate as well as the adaptive immune response to CCA are required ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). Such strategies would couple ICB with immunotherapies targeting immunosuppressive immune cells in CCA. Consequently, a greater understanding of the immunobiology of CCA will direct development of combination immunotherapeutic strategies. Although a T cell-inflamed TIME, high TMB, and even PD-L1 expression may correlate with response in other tumour types, the utility of these biomarkers in CCA is unknown. Accordingly, investigative efforts should also be directed towards development of biomarkers which predict response to immunotherapy in CCA.
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[^1]: Ongoing clinical trials were identified by searching [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0005} using the terms \"Biliary Cancer,\" \"cholangiocarcinoma,\" \"biliary carcinoma,\" \"bile duct,\" or \"biliary tract\" and manually curated for inclusion of an immunotherapy arm. Trials were included with status of \"Recruiting,\" \"Not yet recruiting,\" \"Active, not recruiting,\" \"Completed,\" or \"Enrolling by invitation.\" Trials of general solid tumours were excluded unless a BTC arm or inclusion was specified. Search was updated as of 4/1/19. BTC, biliary tract cancer; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; ICB, immune checkpoint blockade; MMR, mismatch repair; PDAC, pancreatic ductal adenocarcinoma; RFA, radio frequency ablation; SBRT, Stereotactic body radiation therapy; TACE, transarterial chemoembolization; TMB, tumor mutational burden.

[^2]: Ongoing clinical trials were identified by searching [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0015} using the terms \"Biliary Cancer,\" \"cholangiocarcinoma,\" \"biliary carcinoma,\" \"bile duct,\" or \"biliary tract\" and manually curated for inclusion of an immunotherapy arm. Trials were included with status of \"Recruiting,\" \"Not yet recruiting,\" \"Active, not recruiting,\" \"Completed,\" or \"Enrolling by invitation.\" Trials of general solid tumours were excluded unless a BTC arm or inclusion was specified. Search was updated as of 4/1/19. BTC, biliary tract cancer; GI, gastrointestinal; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; MMR, mismatch repair; PDAC, pancreatic ductal adenocarcinoma.

[^3]: Ongoing clinical trials were identified by searching [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0025} using the terms \"Biliary Cancer,\" \"cholangiocarcinoma,\" \"biliary carcinoma,\" \"bile duct,\" or \"biliary tract\" and manually curated for inclusion of an immunotherapy arm. Trials were included with status of \"Recruiting,\" \"Not yet recruiting,\" \"Active, not recruiting,\" \"Completed,\" or \"Enrolling by invitation.\" Trials of general solid tumours were excluded unless a BTC arm or inclusion was specified. Search was updated as of 4/1/19. BTC, biliary tract cancer; CAR, chimeric antigen receptor; CR, complete response; GI, gastrointestinal; iCCA, intrahepatic cholangiocarcinoma.
